Wave Life Sciences (WVE) to Release Earnings on Thursday

Wave Life Sciences (NASDAQ:WVE) will release its earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. The company had revenue of $29.06 million during the quarter, compared to analysts’ expectations of $23.30 million. During the same quarter in the prior year, the business posted ($0.47) earnings per share. On average, analysts expect Wave Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Wave Life Sciences Stock Performance

Shares of NASDAQ WVE opened at $5.79 on Wednesday. Wave Life Sciences has a 1-year low of $3.15 and a 1-year high of $7.67. The business has a fifty day moving average price of $5.72 and a 200 day moving average price of $5.18.

Analyst Ratings Changes

WVE has been the subject of several analyst reports. HC Wainwright increased their price target on shares of Wave Life Sciences from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, March 7th. StockNews.com downgraded shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 18th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $5.00 price target on shares of Wave Life Sciences in a research report on Thursday, March 7th. Finally, Truist Financial reissued a “buy” rating and issued a $17.00 price objective on shares of Wave Life Sciences in a research report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Insider Activity

In other news, CFO Kyle Moran sold 15,630 shares of the stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $6.17, for a total value of $96,437.10. Following the transaction, the chief financial officer now directly owns 33,921 shares of the company’s stock, valued at $209,292.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 31.10% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.